Key result
Atenolol prolongs time to exercise ischemia vs control, while nifedipine shows no benefit.
Why the study?
The importance and therapeutic implications of dynamic coronary stenosis in patients with single-vessel coronary artery disease and exercise-induced ischaemia were not established.
RCT (n=10)
Double-blind
Randomized
Atenolol improves exercise ischaemia threshold in single-vessel CAD with vasomotor variability; supports beta-blockade preference over nifedipine for this phenotype.
Ten patients with proven single-vessel coronary artery disease and a positive exercise test for ischaemia were investigated to establish the importance and therapeutic implications of dynamic coronary stenosis in such patients. All patients interrupted their anti-anginal therapy and under took serial exercise testing in an attempt to identify variability in the ischaemic threshold. Ergonovine testing was performed in nine patients and all underwent 48 h of ambulatory ST segment monitoring while treatment was discontinued. Patients then entered a randomized double-blind study of atenolol and nifedipine; treadmill exercise testing and 48 h of ambulatory ST segment monitoring were performed at the end of each treatment phase. Six (60%) patients showed evidence of variability in coronary vasomotor tone four of whom developed significant ST segment changes during administration of ergonovine; a further two had greater than 30% variability in time to onset of ischaemia during serial treadmill exercise testing. Atenolol significantly increased the time to ischaemia on exercise testing, both in the group as a whole and in the subgroup with evidence of altered vasomotor tone when compared with no therapy, and led to a non-significant reduction in the frequency and duration of ischaemia during the patients' daily lives. Nifedipine, conversely, did not significantly increase time to ischaemia on exercise testing or reduce the frequency or duration of ambulatory ischaemia in either the whole group or the subgroup. With evidence of altered vasomotor tone when compared to no therapy however it was beneficial in terms of reduction in chest pain and requirement for glyceryl trinitrate during daily life.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Mulcahy et al. (1991) conducted an RCT in Single-vessel coronary artery disease (n=10). Atenolol and nifedipine vs. No therapy was evaluated on Time to ischaemia on exercise testing. Atenolol significantly increased the time to ischemia on exercise testing compared with no therapy, whereas nifedipine did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: